Search this Site

Obesity Shortens Lives!

January 25, 2014

From the E-Journal of Age Management Medicine Vol.9, No. 1 • January 2014 Obesity May Shorten Lives By Almost 4 Years: Study And obese middle-aged people die an average of more than 7 years sooner, U.S. statistics show Robert Preidt January 16, 2014 (HealthDay News) — Obese American adults die an average of almost four years earlier than those with normal weight, and middle-aged obese adults face the highest risk of an early death, a new study suggests. One expert wasn’t surprised by the findings. “As we are watching the epidemic of obesity grow, we need to understand the huge implications — not just on chronic illness, but also the effect on life expectancy,” said Dr. Suzanne Steinbaum, a preventive cardiologist at Lenox Hill Hospital in New York City. “It is time that we treat obesity as a medical illness, because, as with other chronic diseases, it causes premature death,” said Steinbaum, who was not involved in the study. In the study, researchers Dr. Luisa Borrell and Lalitha Samuel of the City University of New York reviewed data collected by the U.S. National Health and Nutrition Examination survey between 1988 and 1994, as well as national death statistics through the year 2006. They found that obesity was associated with at least a 20 percent increased risk of death from all causes or from heart disease. Overall, obese adults died 3.7 years earlier from all causes

Posted in Blog, Medical News by rishman
January 23, 2014

From Renal and Urology News Testosterone replacement therapy (TRT) is not associated with an increased risk of cancer-specific or all-cause mortality in patients with prostate cancer (PCa), according to a new study. In fact, PCa patients who received TRT had significantly lower death rates than those who did not, researchers reported online ahead of print in The Journal of Sexual Medicine. Additionally, the study demonstrated that TRT was not associated with an increased likelihood of requiring salvage hormone therapy. Alan L. Kaplan, MD, of the David Geffen School of Medicine at the University of California Los Angeles, and colleagues identified 149,354 men (median age 73 years) diagnosed with PCa from 1992 to 2007 using linked Surveillance, Epidemiology, and End Results-Medicare data. Of these, 1,181 (0.79% received TRT following their cancer diagnosis. TRT use was associated with younger age and higher education. The median follow-up after the PCa diagnosis was eight years for TRT group and six years for the no TRT group. The cancer-specific and overall mortality rates were 0.92 and 5.40 deaths, respectively, per 100 person years in the TRT group compared with 1.57 and 6.88 deaths per 100 person years in the no TRT group. “The reason for lowered mortality rates among men receiving TRT is not clear, but as the Charlson index was approximately the same in the two groups, com

Posted in Blog, Medical News by rishman
January 13, 2014

Raymond Ishman, M.D. President, Cenegenics Philadelphia Director of Quality Assurance, Cenegenics Elite Health At Cenegenics, we bring you perspective on current medical issues as part of our commitment to high quality service. Below is some much needed perspective. A series of recent articles published in The Annals of Internal Medicine received a lot of press because of an editorial entitled “Enough is Enough: Stop Wasting Money on Vitamin and Mineral Supplements.”

  • Authors of the editorial stated – “supplementing the diet of well-nourished adults with (most) mineral or vitamin supplements has no clear benefit and might even be harmful.”
  • The USPTF study that was referenced in the editorial actually concluded that there was limited evidence for benefit of multivitamin/mineral supplementation on heart disease and cancer. However, 2 large trials included in the USPTF study that were greater than 10 years did show a lower risk of cancer in men taking multivitamins.

The authors of the editorial went far beyond what the USPTF study stated, saying that multivitamins are useless, potentially harmful and their use should be discouraged, even though the 2 studies mentioned above did indeed show benefit. They also made misleading statements about antioxidants, folic acid, B-v

Posted in Blog, Medical News by rishman
December 15, 2013

Raymond Ishman, M.D. President, Cenegenics Philadelphia Director of Quality Assurance Cenegenics Elite Health Perhaps you’ve heard the term “Fat and Fit” or know of overweight/obese individuals who have normal cholesterol, blood sugar and blood pressure. They often don’t see the need to lose weight because their “numbers” are good. Doctors are frequently at a loss as to how to motivate these patients to lose weight. A study published December 2, 2013 in the Annals of Internal Medicine should give these patients “food for thought”. This analysis of eight different studies, revealed a 25% increase in all-cause and cardiovascular (heart attack and stroke) mortality in those overweight/obese patients considered “metabolically healthy” (those with normal blood pressure, glucose, cholesterol, etc., and not taking medicine for these conditions). Their conclusion was that “there is no healthy pattern of increased weight.” A study published just two weeks earlier in the Journal of Clinical Endocrinology and Metabolism found that so-called MHO (metabolically healthy obese) had 4 times the risk of developing both diabetes and heart disease compared with metabolically healthy people of normal weight. In the US, we have a very distorted image of obesity. Normal weight individuals are often considered “skinny.” What most Americans would consider “overweight,”

Posted in Blog, Medical News by rishman
November 14, 2013

Raymond Ishman, M.D. President, Cenegenics Philadelphia Director of Quality Assurance Cenegenics Elite Health A recent Veteran’s Administration study published in JAMA, the Journal of the American Medical Association, has received much media attention, raising fears regarding the use of testosterone replacement in aging men. The study had multiple flaws that limit its usefulness. Some of these flaws include:

  • This was an observational study. These types of studies do not show cause and effect.
  • Subjects in this study were relatively sick with advanced coronary disease.
  • Only 60% of study patients received one follow up blood study to see if their blood levels had improved.
  • Of those that had follow up testosterone levels, the average level was only 332 with the “normal range” being 250-1100. This could hardly be considered a therapeutic level.

The results of this study are contrary to the vast majority of studies supporting the benefits of testosterone replacement. Other studies using better methodology have concluded that:

  • “In men with low testosterone levels, testosterone treatment was associated with a decreased mortality compared with no testosterone treatment.” (Journal of Clinical Endocrinology and Metabolism, 2012)
  • “…testosterone concentrations are inversely related to mortality due to cardiovascu

Posted in Blog, Medical News by rishman
October 9, 2013

Raymond Ishman, M.D. President, Cenegenics Philadelphia Director of Quality Assurance Cenegenics Elite Health The media attention surrounding publication of the initial results of the Women’s Health Initiative (WHI) in 2002 led to much fear and confusion regarding the use of hormone therapy (HT) after menopause. This led to a dramatic reduction in prescriptions for HT in the United States and around the world. Although in 2002 it was stated that the results pertained to all women receiving HT, subsequent analyses of data from the Women’s Health Initiative (WHI) and others clearly showed that “younger women and those within 10 years of menopause had a very beneficial (overall) risk-to-benefit ratio.” A Study published in July of 2013 in the American Journal of Public Health estimates that “Over a 10-year span, starting in 2002, a minimum of 18,601 and as many as 91,610 postmenopausal women died prematurely because of the avoidance of estrogen therapy.” Their conclusion was that “Estrogen therapy in younger postmenopausal women is associated with a decisive reduction in all-cause mortality, but estrogen use in this population is low and continuing to fall.” According to a 2013 article in The Journal of Clinical Endocrinology and Metabolism, even data from WHI revealed:

  • A protective effect for coronary disease and a reduction in m

Posted in Blog, Medical News by rishman
July 31, 2013

Raymond Ishman, M.D. President, Cenegenics Philadelphia Director of Quality Assurance Cenegenics Elite Health

A handful of recent studies have linked omega-3 oils (or fish oil) to increased risk for prostate cancer, a claim that has obviously caused many of you a great deal of concern. In matters of health, it is important to look at a broad base of research and separate fact from fiction – which is what I’ll do in the following paragraphs. Let me start by stating that, despite these recent claims, I’ll continue taking my fish oil! We at Cenegenics continue to advocate the use of fish oils for their well-documented beneficial effects related to cardiovascular disease, cognitive function and arthritis. Contrary the recent study, the vast majority of medical research suggests that fish oil has no relationship to prostate cancer. Several studies even indicate it may prevent cancer. Here are a few examples:

  • The rate of prostate cancer in the US is roughly 10 times higher than in Japan, where fish oil consumption is 8 times higher.
  • The same team behind the most recent report linking prostate cancer to fish oil concluded in 2011 that the use of fish oil supplements was not associated with an increased risk for prostate cancer.
  • A 2010

Posted in Blog, Medical News by rishman
November 12, 2012

Raymond Ishman, M.D. President, Cenegenics Philadelphia Director of Quality Assurance Cenegenics Elite Health The Women’s Health Initiative (WHI) study was prematurely stopped in 2002 due to a reported increase in the incidence of breast cancer in women in the hormone replacement arm of the study. As a result, thousands of women have stopped, or been taken off their hormones unnecessarily. This has lead to needless confusion, suffering and fear, to the point of hysteria in some, regarding the use of hormone replacement therapy (HRT). Since then, many of the main findings of this study have been debunked, albeit with much less media attention. Multiple studies have challenged the conclusions of WHI. One such study was published in the British Medical Journal and released October 9, 2012. The data came from the Danish Osteoporosis Prevention Study where recently postmenopausal women, ages 45-58, were treated with or without HRT for 10 years. The original study was actually started in the early 1990s. Hormones were stopped at 10 years when the results of the Women’s Health Initiative (WHI) study were released in 2002, with follow up carried out until 2008. In the current report, the same data was analyzed for cardiovascular outcomes, cancer and overall mortality. In the Danish study, women who previously had a hysterectomy were given oral bioidentical estradiol. (Topical is no

Posted in Blog, Medical News by rishman